Vol. 50 | No. 1 | January-June 2022 Back

Open Access

Low-Dose Thrombolysis in an Intermediate High-Risk Submassive Pulmonary Embolism With Right Atrial Thrombus: A Case Report

Joyce Karla Suero, Irene Patiño, Jeffrey Mendoza
Jun 2022 DOI 10.69944/pjc.56bfee39bf

Abstract

BACKGROUND: Venous thromboembolism, encompassing pulmonary embolism (PE) and deep  vein thrombosis (DVT), is the third most common acute cardiovascular syndrome. It requires  prompt diagnosis and risk-based treatment strategies. 

CASE: A 47-year-old male, 30-pack-year smoker who recently underwent open reduction and  internal fixation of the right femur presented with dyspnea. There was no hemodynamic instability.  Twelve-lead electrocardiogram showed sinus rhythm with incomplete right bundle-branch  block, and troponin was elevated. Chest x-ray showed dilated right descending pulmonary  artery. Two-dimensional echocardiogram revealed right atrial thrombus with right ventricular  dysfunction. Computed tomography of the pulmonary artery confirmed massive PE with infarct  on the posterobasal segment of the right lower lobe. Venous duplex scan of the lower extremities  showed an acute DVT of the right femoral vein, popliteal vein, and peroneal vein. Anticoagulation  was started. With a dilemma of a recent surgery in an intermediate high-risk submassive  PE, options other than guideline-recommended systemic thrombolysis were considered. A  multidisciplinary consensus recommended the administration of low-dose thrombolysis, which  later resulted to clinical improvement. 

CONCLUSION: This is the first documented local case of successful resolution of a right  atrial thrombus with pulmonary thrombus and DVT using low-dose thrombolysis, without  complications of bleeding, in a patient with contraindications to thrombolysis. With more clinical  experience and studies of low-dose recombinant tissue plasminogen activator in this special  population, it can offer a promising treatment option. 

KEYWORDS: pulmonary embolism, submassive, low-dose systemic thrombolysis,  contraindication for thrombolysis, alteplase, tPA, right atrial thrombus

References
  1. Zipes D, Libby P, Bonow R, Mann D, Tomaselli G, Braunwald E. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 11th ed. Elsevier; 2019:1681– 1698.
  2. Sharifi M, Bay C, Skrocki L, et al. Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” trial). Am J Cardiol 2013;111:273–277.
  3. Mi YH, Liang Y, Lu YH, et al. Recombinant tissue plasminogen activator plus heparin compared with heparin alone for patients with acute submassive pulmonary embolism: one-year outcome. J Geriatr Cardiol 2013;10:323–329.
  4. Layman SN, Guidry TJ, Gillion AR. Low-dose alteplase for the treatment of submassive pulmonary embolism: a case series [published online June 19, 2019]. J Pharm Pract 2019;897190019855164. doi:10.1177/0897190019855164.
  5. Seguban JM, Alajar E, Isidro J, Pestaño N, Punzalan FE, Castillo R. Concurrent massive pulmonary embolism with emboli in transit and anterior ST elevation myocardial infarction with increased bleeding risk successfully treated with low-dose systemic alteplase: a case report. Cardiol Cardiovasc Med 2019;3:352–359.
  6. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Respir J 2019;54(3):1901647.
  7. Martin C, Sobolewski K, Bridgeman P, Boutsikaris D. Systemic thrombolysis for pulmonary embolism: a review. P T. 2016;41(12):770–775.
  8. Aggarwal V, Nicolais C, Lee A, Bashir R. Acute management of pulmonary embolism. October 24, 2017. https://www.acc.org/latest-in-cardiology/ articles/2017/10/23/12/12/acute-management-of pulmonary-embolism.
  9. Sabri SS, Saad WEA, Turba UC, Park AW, Angle JF, Matsumoto AH. Percutaneous pulmonary embolectomy: indications, techniques and outcomes. Vasc Dis Manage 2010;7:E223–E229.
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.